Traditionally, antitrust analysis had no method to quantify the benefits of better health care outcomes from a potential merger to balance them against the potential for increased costs. However, a branch of health care economics allows for that calculation. This approach has not been used in antitrust analysis to date, but United States law is flexible enough to allow such an approach, and the 2010 Horizontal Merger Guidelines contemplate it in Section 5. It enables us to use established procedures to put quality of care into health care merger analysis.
"Taking Quality of Health Care Seriously in Provider Merger Analysis,"
Saint Louis University Journal of Health Law & Policy: Vol. 11
, Article 9.
Available at: https://scholarship.law.slu.edu/jhlp/vol11/iss1/9